SCHEMBL33619

SCHEMBL33619

CCCCCCCCCCCCCCCCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCCCCC

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 5/20 0.72
MAPT P10636 5/20 0.72
LMNA P02545 6/20 0.68
ALDH1A1 P00352 1/20 0.68
PRKCA P17252 1/20 0.62
PRKCE Q02156 1/20 0.62
PRKCQ Q04759 1/20 0.62
PRKCD Q05655 1/20 0.62
MEN1 O00255 3/20 0.57
GMNN O75496 3/20 0.57
KMT2A Q03164 3/20 0.57
NPSR1 Q6W5P4 3/20 0.57
TP53 P04637 3/20 0.57
TSHR P16473 3/20 0.57
CYP1A2 P05177 2/20 0.57
HSP90AA1 P07900 2/20 0.57
BLM P54132 2/20 0.57
NR1H4 Q96RI1 2/20 0.57
CYP2C9 P11712 2/20 0.57
HIF1A Q16665 2/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20516371 1.00 MAPK1 (0.72) MAPK1MAPTLMNAALDH1A1PRKCA
SCHEMBL22187086 1.00 MAPK1 (0.72) MAPK1MAPTLMNAALDH1A1PRKCA
SCHEMBL20512293 1.00 MAPK1 (0.72) MAPK1MAPTLMNAALDH1A1PRKCA
SCHEMBL22986095 1.00 MAPK1 (0.72) MAPK1MAPTLMNAALDH1A1PRKCA
SCHEMBL23581586 1.00 MAPK1 (0.72) MAPK1MAPTLMNAALDH1A1PRKCA
SCHEMBL22420022 1.00 MAPK1 (0.72) MAPK1MAPTLMNAALDH1A1PRKCA
SCHEMBL23568445 1.00 MAPK1 (0.72) MAPK1MAPTLMNAALDH1A1PRKCA
SCHEMBL24305193 1.00 MAPK1 (0.72) MAPK1MAPTLMNAALDH1A1PRKCA
SCHEMBL25125676 1.00 MAPK1 (0.72) MAPK1MAPTLMNAALDH1A1PRKCA
SCHEMBL20512295 1.00 MAPK1 (0.72) MAPK1MAPTLMNAALDH1A1PRKCA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1860 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250312263-A1 SKIN CARE COMPOSITIONS COLGATE-PALMOLIVE COMPANY (US) 2025-10-09 US claimed
US-20250269034-A1 TOPICAL TETRACYCLINE COMPOSITIONS JOURNEY MEDICAL CORP (US) 2025-08-28 US claimed
US-12138311-B2 Topical tetracycline compositions JOURNEY MEDICAL CORPORATION (US) 2024-11-12 US claimed
WO-2023110424-A1 COSMETIC COMPOSITION COMPRISING A BIS-AMINO SILICONE, A CATIONIC SURFACTANT, A FATTY ALCOHOL AND A FATTY ALCOHOL ESTER, COSMETIC TREATMENT PROCESS AND USE L'OREAL (FR) 2023-06-22 WO claimed
US-20230060379-A1 FULLERENE AND ITS USE TO MAINTAIN GOOD HEALTH AND TO PROLONG THE EXPECTED LIFESPAN OF MAMMALS Moussa, Fathi (FR) 2023-03-02 US claimed
US-10946101-B2 Surfactant-free water-free foamable compositions, breakable foams and gels and their uses VYNE THERAPEUTICS INC. (US) 2021-03-16 US claimed
US-20210015927-A1 SURFACTANT-FREE WATER-FREE FOAMABLE COMPOSITIONS, BREAKABLE FOAMS AND GELS AND THEIR USES SWK FUNDING LLC 2021-01-21 US claimed
US-20200261586-A1 TOPICAL TETRACYCLINE COMPOSITIONS FOAMIX PHARMACEUTICALS LTD. (IL) 2020-08-20 US claimed
US-20190134204-A1 SURFACTANT-FREE WATER-FREE FOAMABLE COMPOSITIONS, BREAKABLE FOAMS AND GELS AND THEIR USES SWK FUNDING LLC 2019-05-09 US claimed
US-10238746-B2 Surfactant-free water-free foamable compositions, breakable foams and gels and their uses FOAMIX PHARMACEUTICALS LTD (IL) 2019-03-26 US claimed
US-20100008880-A1 Clear Cosmetic Compositions And Methods Of Using ELC MANAGEMENT LLC 2010-01-14 US claimed
US-20090068219-A1 Anti-wrinkle hormone-type cosmetic composition 3LAB, INC. (US) 2009-03-12 US claimed
EP-2023886-A2 CLEAR COSMETIC COMPOSITIONS AND METHODS OF USE ELC Management LLC (US) 2009-02-18 EP claimed
WO-2007130802-A2 CLEAR COSMETIC COMPOSITIONS AND METHODS OF USE ELC MANAGEMENT LLC (US) 2007-11-15 WO claimed
US-20070259012-A1 Clear Cosmetic Compositions and Methods Of Use CASTRO JOHN 2007-11-08 US claimed
US-20050069511-A1 Cosmetic compositions containing a starch and an ester and the use thereof L'OREAL (FR) 2005-03-31 US claimed
EP-1395234-A1 COSMETIC COMPOSITIONS CONTAINING A STARCH AND AN ESTER AND THE USE THEREOF L'OREAL (FR) 2004-03-10 EP claimed
US-6589519-B1 Smoothness, softness; shampoo L'OREAL S.A. (FR) 2003-07-08 US claimed
EP-1009366-B1 COSMETIC COMPOSITIONS COMPRISING A POLYOXYALKYLATED AMINATED SILICONE BLOCK POLYMER AND A CONDITIONING AGENT AND THEIR USE OREAL (FR) 2003-03-26 EP claimed
WO-2002094207-A1 COSMETIC COMPOSITIONS CONTAINING A STARCH AND AN ESTER AND THE USE THEREOF L'OREAL (FR) 2002-11-28 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050069511-A1 Cosmetic compositions containing a starch and an ester and the use thereof CUTA, H1-10, C1S MAPK1 1719/4885MAPT 1625/4885LMNA 806/4885
US-20250312263-A1 SKIN CARE COMPOSITIONS CUTA, CD44, DSG1 MAPK1 1692/4885MAPT 2493/4885LMNA 899/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.